At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CUE Cue Biopharma, Inc.
Pre-Mkt 06-12 04:05:38 EDT
27.09
-0.77
-2.76%
High28.96Low27.00Vol43.60K
Open27.60D1 Closing27.86Amplitude7.03%
Mkt Cap113.79MTradable Cap104.38MTotal Shares4.20M
T/O1.20MT/O Rate1.13%Tradable Shares3.85M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cue Biopharma files initial beneficial ownership statement for VP, principal accounting officer Michael Meluzio
Reuters  ·  05:49
Cue Biopharma files initial beneficial ownership statement for VP, principal accounting officer Michael Meluzio
Cue Biopharma Chief Legal Compliance Officer Ray Sumita files initial beneficial ownership statement
Reuters  ·  05:48
Cue Biopharma Chief Legal Compliance Officer Ray Sumita files initial beneficial ownership statement
Cue Biopharma director Daniel A. Camardo files initial beneficial ownership statement
Reuters  ·  06-09
Cue Biopharma director Daniel A. Camardo files initial beneficial ownership statement
Cue Biopharma shareholders approved 2026 stock incentive plan at special meeting
Reuters  ·  06-04
Cue Biopharma shareholders approved 2026 stock incentive plan at special meeting
Cue Biopharma director Meehan Viola Mong files initial beneficial ownership statement
Reuters  ·  06-03
Cue Biopharma director Meehan Viola Mong files initial beneficial ownership statement
Cue Biopharma announces board transition, appoints two new directors
TIPRANKS  ·  06-03
Cue Biopharma announces board transition, appoints two new directors
Cue Biopharma adds Daniel Camardo, Viola Meehan to board amid director exits
Reuters  ·  06-03
Cue Biopharma adds Daniel Camardo, Viola Meehan to board amid director exits
Cue Biopharma Announces Board Transition and Addition of New Directors With Continued Company Evolution
THOMSON REUTERS  ·  06-03
Cue Biopharma Announces Board Transition and Addition of New Directors With Continued Company Evolution
Cue Biopharma CEO presents at Jefferies Global Healthcare Conference
Reuters  ·  05-22
Cue Biopharma CEO presents at Jefferies Global Healthcare Conference
Cue Biopharma Q1 EPS $(1.08) Misses $(0.10) Estimate, Sales $5.686M Beat $1.875M Estimate
Benzinga  ·  05-15
Cue Biopharma Q1 EPS $(1.08) Misses $(0.10) Estimate, Sales $5.686M Beat $1.875M Estimate
Cue Biopharma Q1 FY26 net loss narrows to $5.18 million; revenue rises to $5.69 million
Reuters  ·  05-15
Cue Biopharma Q1 FY26 net loss narrows to $5.18 million; revenue rises to $5.69 million
Cue Biopharma grants CEO stock options for 655,074 shares at $30.42 each
Reuters  ·  05-08
Cue Biopharma grants CEO stock options for 655,074 shares at $30.42 each
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  05-08
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cue Biopharma CEO, director Shao-Lee Lin files initial beneficial ownership statement
Reuters  ·  05-08
Cue Biopharma CEO, director Shao-Lee Lin files initial beneficial ownership statement
Cue Biopharma trading resumes
TIPRANKS  ·  05-05
Cue Biopharma trading resumes
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:27 PM
Reuters  ·  05-05
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:27 PM
BUZZ-U.S. STOCKS ON THE MOVE-Perella Weinberg Partners, Amkor Technology, Esperion Therapeutics
Reuters  ·  05-02
BUZZ-U.S. STOCKS ON THE MOVE-Perella Weinberg Partners, Amkor Technology, Esperion Therapeutics
BUZZ-U.S. STOCKS ON THE MOVE-Paramount Skydance, Newell Brands, Rhythm,
Reuters  ·  05-01
BUZZ-U.S. STOCKS ON THE MOVE-Paramount Skydance, Newell Brands, Rhythm,
Cue Biopharma Shares Jump 110% After Co Names New CEO, New License Agreement and $30 Mln Private Placement
THOMSON REUTERS  ·  05-01
Cue Biopharma Shares Jump 110% After Co Names New CEO, New License Agreement and $30 Mln Private Placement
Top Premarket Gainers
MT Newswires Live  ·  05-01
Top Premarket Gainers

Introduction

Company Name.
Cue Biopharma, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Issue price:
--